MDGL · Madrigal Pharmaceuticals, Inc.
$534.49
+0.26% last session
End-of-day data · close of 2026-09-11
Market cap
$12B
Enterprise value
$12B
Trailing P/E
—
Forward P/E
55.4
Dividend yield
—
Beta
-0.99
Avg volume
0M
Employees
1K
Daily Change %
0.26%
5 Days Change
1.03%
10 Days Change
1.23%
30 Days Change
2.13%
60 Days Change
1.86%
Month to Day Change
1.48%
Year to Day Change
-6.13%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MDGL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-04
Latest call per bank · past 12 months
Barclays
Overweight$962
+80.4% vs priceWells Fargo
Overweight$685
+28.5% vs priceBank of America
Neutral$542
+1.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-04 | Wolfe Research | Upgrade | Peer Perform → Outperform | $0.00 → $605 |
| 2026-08-03 | Barclays | Maintains | Overweight | $964 → $962 |
| 2026-07-29 | Canaccord Genuity | Maintains | Buy | $578 → $587 |
| 2026-07-27 | Wells Fargo | Initiates | Overweight | $0.00 → $685 |
| 2026-06-11 | Bank of America | Maintains | Neutral | $550 → $542 |
| 2026-05-13 | Truist Securities | Maintains | Buy | $640 → $709 |
| 2026-05-07 | Canaccord Genuity | Maintains | Buy | $587 → $578 |
| 2026-05-07 | Evercore ISI Group | Maintains | Outperform | $652 → $649 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 51 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.7% above the 50-day MA ($530.74).
- Price vs 200-day MA: Trading 3.8% above the 200-day MA ($515.02).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.15) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($412.35) and high ($602.83).
MDGL Price Chart
Loading chart for MDGL…
Fundamentals
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.